On Nov. 9, FDA Requires Expanded Eye Warning on All GLP-1 Drugs
Key Facts
On Nov. 9, 2026, the U.S. Food and Drug Administration said it will require holders of licenses for all glucagon-like peptide-1 receptor agonist drugs to add information about a possible increased risk of non-arteritic anterior ischemic optic neuropathy to the Warnings and Precautions section of their labels. The decision extends the warning to all products in this class currently on the market, after cases associated with them were reported. The agency describes the condition as rare, but says it may lead to a sudden, painless decline in vision in one eye. Vision loss may be permanent, according to safety information cited by the agency. The update puts this possibility among the information patients and caregivers should review when using these drugs.
The FDA said reports of optic neuropathy cases had been received for all GLP-1 products currently on the market. But it noted that risk factors associated with the condition overlap substantially with diseases common among users of these drugs, making adverse-event reports difficult to interpret. This means that the condition’s occurrence in a drug user is not by itself enough to determine its cause. In its announcement, the agency did not establish that treatment caused the reported cases; it framed the action as a warning about a possible increased risk. The announced decision therefore focuses on updating labels and guiding patients and doctors on symptoms and appropriate medical steps.
The agency recommends that patients tell their healthcare provider immediately if they experience sudden, painless vision loss or impairment in one eye. If a doctor suspects the condition, the FDA recommends promptly referring the patient to an eye doctor for evaluation. It also recommends considering stopping the drug if the condition is suspected, unless the benefits of treatment outweigh its risks. These instructions make clear that managing symptoms begins with urgent medical evaluation, while the decision to continue treatment should be considered by weighing benefits against risks. The information provided did not specify a separate date for the label updates to take effect.
The FDA says the condition results from reduced blood flow to the front part of the optic nerve, and that its underlying cause is not fully understood. Potential risk factors include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. The UK medicines regulator updated information on semaglutide on Feb. 5, 2026, estimating that the condition may affect up to 1 in 10,000 people taking the drug. A European review of the evidence, according to the MHRA, indicated that relative risk may roughly double in adults with type 2 diabetes, equivalent to about one additional case per 10,000 people treated each year. The review noted conflicting published evidence, while the UK agency said it was reviewing evidence on a possible link between other GLP-1 drugs and the condition.
In its data on semaglutide, the MHRA said the UK reporting system had received 3 spontaneous reports suspected of being associated with the condition as of Aug. 1, 2025. The agency estimated that about 10.2 million packs of the drug had been dispensed over the previous five years. It cautioned that reporting a case does not mean the drug definitely caused it. This reflects the limits of what can be inferred from adverse-event reports alone, particularly given overlapping risk factors and conflicting published evidence. The expanded U.S. warning comes as the UK review had focused on semaglutide, while the MHRA continues to review evidence on the rest of the drug class.